Seroatlas · Human Serome Atlas

SYT9

Synaptotagmin-9

Also known as: SYT9_HUMAN

Cross-references: UniProt · Ensembl · Human Protein Atlas · GeneCards · NCBI Gene

Protein identityUniProt · HPA

UniProt accession: Q86SS6
Gene: SYT9
Ensembl: ENSG00000170743
Chromosome: 11
Canonical length: 491 aa
Protein class: Predicted membrane proteins
Quaternary structure: Homodimer

OverviewNCBI Gene

Predicted to enable SNARE binding activity; calcium ion sensor activity; and calcium-dependent phospholipid binding activity. Predicted to be involved in chemical synaptic transmission; regulation of vesicle-mediated transport; and vesicle-mediated transport. Predicted to be located in clathrin-coated endocytic vesicle membrane. Predicted to be active in hippocampal mossy fiber to CA3 synapse; plasma membrane; and secretory vesicle. [provided by Alliance of Genome Resources, Apr 2025]

Canonical amino-acid sequenceUniProt

491 residues, UniProt reviewed canonical sequence.

>Q86SS6|SYT9
     1  MPGARDALCH QALQLLAELC ARGALEHDSC QDFIYHLRDR ARPRLRDPDI SVSLLTLVVT
    61  ACGLALFGVS LFVSWKLCWV PWRERGLPSG SKDNNQEPLN YMDTETNEQE NSEDFLDPPT
   121  PCPDSSMKIS HTSPDIPLST QTGIQENCAH GVRVQRQVTE PTSSARHNSI RRQLNLSNPD
   181  FNIQQLQKQE QLTGIGRIKP ELYKQRSLDN DDGRRSNSKA CGKLNFILKY DCDLEQLIVK
   241  IHKAVNLPAK DFSGTSDPYV KIYLLPDRKT KHQTKVHRKT LNPVFDEVFL FPVPYNDLEA
   301  RKLHFSVYDF DRFSRHDLIG QVVVDHFLDL ADFPRECILW KDIEYVTNDN VDLGELMFSL
   361  CYLPTAGRLT ITIIKARNLK AMDITGASDP YVKVSLMCDG RRLKKRKTST KRNTLNPVYN
   421  EAIVFDVPPE NIDQIHLSIA VMDYDRVGHN EIIGVCQVGN EAERLGRDHW SEMLSYPRKP
   481  IAHWHSLVEK R

LocalizationUniProt · AlphaFold · HPA

Whether an antibody against SYT9 can act on the native protein depends on physical access: surface and secreted proteins are reachable by circulating antibodies, intracellular proteins usually are not.

Antibody reachability: Intracellular
Secreted: No
Transmembrane segments: 1
Mean surface accessibility (rSASA): 0.44
Highest tissue expression: 8.4 nTPM

Expression across tissuesHPA

Tissue

cerebellum: 8.4 nTPM
retina: 7 nTPM
spinal cord: 4.4 nTPM
midbrain: 3.5 nTPM
liver: 3.4 nTPM
seminal vesicle: 3.3 nTPM

Single-cell type

oligodendrocytes: 190 nCPM
cardiomyocytes: 178 nCPM
retinal bipolar cells: 152 nCPM
podocytes: 111 nCPM
gonadotrophs: 96 nCPM
astrocytes: 96 nCPM

Immune cell

basophil: 0 nTPM
classical monocyte: 0 nTPM
eosinophil: 0 nTPM
gdT-cell: 0 nTPM
intermediate monocyte: 0 nTPM
MAIT T-cell: 0 nTPM

Brain region

thalamus: 37 nTPM
midbrain: 29 nTPM
cerebellum: 28 nTPM
white matter: 27 nTPM
medulla oblongata: 25 nTPM
pons: 24 nTPM

Genetic constraint and essentialitygnomAD · DepMap

Does the body need this protein intact? Low LOEUF or a strong DepMap dependency means loss or blockade of the protein is likely to be felt.

gnomAD LOEUF (loss-of-function intolerance): 0.49
gnomAD pLI: 0.31
gnomAD missense Z: 1.32
DepMap mean gene effect: 0.09
DepMap dependency class: none

Cancer expressionTCGA

Across TCGA tumor cohorts, this protein is over-expressed in roughly 2% of surveyed tumor types (aggregate summary; per-cohort expression, alteration, and survival load in the interactive view).

OntologyGO

Biological processes

Molecular functions

Cellular components

Protein domainsUniProt · Pfam · InterPro

KeywordsUniProt

Antibody and autoantibody relevanceSeroatlas analysis

Seroatlas reads SYT9 as an antibody target. Whether an autoantibody or antibody against SYT9 could matter depends on whether native SYT9 is physically reachable, whether the body needs it intact, and whether it acts in a disease-relevant tissue.

SYT9 is annotated as predominantly intracellular. Intracellular proteins are common autoantibody markers, becoming visible to the immune system after cell injury or altered processing, but are usually markers of disease rather than direct drivers.

Annotation status

The present source text does not explicitly label SYT9 as an autoantigen. Seroatlas presents hypothesis context only and does not manufacture a known-serology claim.

Loading the interactive Seroatlas protein explorer...